News & Updates

Original New Drug Application Approvals by US FDA (01-15 March 2023)

16 Mar 2023

New drug applications approved by US FDA as of 01-15 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 March 2023)

16 Mar 2023

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

15 Mar 2023

Using methylphenidate and a selective serotonin reuptake inhibitor (SSRI) together does not appear to pose any significant risk, with both agents having been shown to be safe in adolescent patients with attention deficit-hyperactivity disorder (ADHD) and depression, according to a new-user cohort study.

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

15 Mar 2023

Small for gestational age tied to reduced lung function in middle age

14 Mar 2023 by

Being born small for gestational age (SGA) appears to contribute to a reduced lung function during middle age, reveals a study.

Small for gestational age tied to reduced lung function in middle age

14 Mar 2023

Pravastatin exposure during pregnancy carries no adverse neurodevelopmental risk for offspring

11 Mar 2023

Children born to mothers who were taking pravastatin during the second and third trimesters of pregnancy do not appear to have any identifiable long-term neurodevelopmental safety risks, as reported in a study.

Pravastatin exposure during pregnancy carries no adverse neurodevelopmental risk for offspring

11 Mar 2023

Prenatal exposure to plastic chemicals ups asthma risk in male offspring

09 Mar 2023

Prenatal exposure to plastic-derived chemicals, such as bisphenol A (BPA) and phthalates, tends to increase the risk of asthma, particularly in males, a study has shown.

Prenatal exposure to plastic chemicals ups asthma risk in male offspring

09 Mar 2023

Sugar-sweetened beverage intake promotes weight gain in children, adults

06 Mar 2023

Consumption of sugar-sweetened beverages (SSBs) may lead to higher body mass index (BMI) and body weight in both children and adults, as shown in a systematic review and meta-analysis.

Sugar-sweetened beverage intake promotes weight gain in children, adults

06 Mar 2023

Original New Drug Application Approvals by US FDA (16-28 February 2023)

28 Feb 2023

New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2023)

28 Feb 2023

Labetalol, nifedipine equally effective for chronic hypertension in pregnancy

23 Feb 2023 by

Treatment with either labetalol or nifedipine is similarly effective in reducing adverse maternal outcomes among women with mild chronic hypertension (CHTN) in pregnancy, according to a study presented at SMFM 2023.

Labetalol, nifedipine equally effective for chronic hypertension in pregnancy

23 Feb 2023

Atropine eye drops may lower incidence of myopia in kids

20 Feb 2023 by

Nightly use of 0.05% atropine eye drops among children appears to lead to a significantly lower incidence of near-sightedness, as shown in the results of the LAMP2 study from Hong Kong.

Atropine eye drops may lower incidence of myopia in kids

20 Feb 2023

Original-New-Drug-Application-Approvals-by-US-FDA--01-15-February-2023

20 Feb 2023

New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--01-15-February-2023

20 Feb 2023

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (01-15 March 2023)

Original New Drug Application Approvals by US FDA (01-15 March 2023)

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

Concurrent use of methylphenidate, selective serotonin reuptake inhibitor generally safe

Small for gestational age tied to reduced lung function in middle age

Small for gestational age tied to reduced lung function in middle age

Pravastatin exposure during pregnancy carries no adverse neurodevelopmental risk for offspring

Pravastatin exposure during pregnancy carries no adverse neurodevelopmental risk for offspring

Prenatal exposure to plastic chemicals ups asthma risk in male offspring

Prenatal exposure to plastic chemicals ups asthma risk in male offspring

Sugar-sweetened beverage intake promotes weight gain in children, adults

Sugar-sweetened beverage intake promotes weight gain in children, adults

Original New Drug Application Approvals by US FDA (16-28 February 2023)

Original New Drug Application Approvals by US FDA (16-28 February 2023)

Labetalol, nifedipine equally effective for chronic hypertension in pregnancy

Labetalol, nifedipine equally effective for chronic hypertension in pregnancy

Atropine eye drops may lower incidence of myopia in kids

Atropine eye drops may lower incidence of myopia in kids

Original-New-Drug-Application-Approvals-by-US-FDA--01-15-February-2023

Original-New-Drug-Application-Approvals-by-US-FDA--01-15-February-2023